Evaluation of CMV/EBV-CMI in Haploid HSCT

The First Affiliated Hospital of Soochow University60 enrolled

Overview

The purpose of this prospective, open-label, Single Arm, single-center study is to evaluate the cytomegalovirus and Epstein-Barr virus specific immune reestablishment for patients with hemopathy undergoingin prophylaxis for cytomegalovirus in haploid hematopoietic stem cell transplantation(haplo-HSCT) .

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hematopoietic Stem Cell Transplantation Cytomegalovirus Infections Epstein-Barr Virus Infections

Interventions

CMV/EBV-CMIDIAGNOSTIC_TEST

The CMV/EBV-CMI is tested before conditioning regimen and 30 days, 45 days, 60 days, 90 days, 120 days, 180 days after transplantation.

Eligibility

Sex: ALLMin age: 16 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. All patients were diagnosed with hemopathy. 2. All patients should have the indication of Haploidentical hematopoietic stem cell transplant and receive the prophylaxis for cytomegalovirus. 3. All patients should sign an informed consent document indicating that they understand the purpose of and procedures required for the study and be willing to participate in the study. Exclusion Criteria: Patients with any conditions not suitable for the trial (investigators' decision).

Locations (1)

First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

RECRUITING

Outcomes

Primary Outcomes

CMV-CMI

CMV specific immune reconstitution from pre-HSCT to 180 days after HSCT

Time frame: 6 months after transplantation

EBV-CMI

EBV specific immune reconstitution from pre-HSCT to 180 days after HSCT

Time frame: 6 months after transplantation